Hemispherx Biopharma gets EMA orphan medicine designation for Ampligen to treat Ebola Virus Disease
Thomas K. Equels, Executive Vice Chairman, states, "European Medicines Agency designation of Ampligen(R)/rintatolimod as an orphan drug is an important achievement in our path seeking commercial approval of